title: [A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].
abstract: We report a case of advanced colon cancer that was effectively treated with mFOLFOX6 plus panitumumab combination chemotherapy. The patient was a 54-year-old man who had type 2 colon cancer of the rectum. An abdominal CT scan demonstrated rectal cancer with bulky lymph node metastasis and 1 hepatic node (rectal cancer SI [bladder retroperitoneum], N2M0H1P0, cStage IV). He was treated with mFOLFOX6 plus panitumumab as neoadjuvant chemotherapy. After 4 courses of chemotherapy, CT revealed that the primary lesion and regional metastatic lymph nodes had reduced in size (rectal cancer A, N1H1P0M0, cStage IV). Anterior rectal resection with D3 nodal dissection and left lateral segmentectomy of the liver was performed. The histological diagnosis was tubular adenocarcinoma (tub2-1), int, INF a, pMP, ly0, v0, pDM0, pPM0, R0. He was treated with 4 courses of mFOLFOX6 after surgery. The patient has been in good health without a recurrence for 2 years and 5 months after surgery. This case suggests that induction chemotherapy with mFOLFOX6 plus panitumumab is a potentially effective regimen for advanced colon cancer.
authors.affiliation: Dept. of Gastroenterology, Fuchu Hospital.
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Yukawa
authors.forename: Yasutake
authors.initials: Y
authors.lastname: Uchima
authors.forename: Minori
authors.initials: M
authors.lastname: Kawamura
authors.forename: Osami
authors.initials: O
authors.lastname: Takeda
authors.forename: Hajime
authors.initials: H
authors.lastname: Hanno
authors.forename: Shigenori
authors.initials: S
authors.lastname: Takayanagi
authors.forename: Tomoomi
authors.initials: T
authors.lastname: Hirooka
authors.forename: Toshio
authors.initials: T
authors.lastname: Dozaiku
authors.forename: Takashi
authors.initials: T
authors.lastname: Hirooka
authors.forename: Naoki
authors.initials: N
authors.lastname: Aomatsu
authors.forename: Toshiki
authors.initials: T
authors.lastname: Hirakawa
authors.forename: Takehiko
authors.initials: T
authors.lastname: Iwauchi
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nishii
authors.forename: Junya
authors.initials: J
authors.lastname: Morimoto
authors.forename: Kazunori
authors.initials: K
authors.lastname: Nakazawa
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takeuchi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D060828:Induction Chemotherapy; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077544:Panitumumab; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000911:Antibodies, Monoclonal; D009944:Organoplatinum Compounds; D000077544:Panitumumab; D002955:Leucovorin; D005472:Fluorouracil